EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine

Sabine Lindquist, Martin Stangel

Neuropsychiatric Disease and Treatment · 2011-05 · 341

DOI: 10.2147/ndt.s10464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropsychiatric Disease and Treatment, 2011-05. Verfasst von Sabine Lindquist und 1 weiteren Autor:innen. Beteiligte Einrichtung: Section Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

3,4-diaminopyridineLambert–Eaton myasthenic syndromeamifampridinemanagementsymptomatic treatment

Autor:innen und Institutionen

  • Section Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany.

Zitieren

APA

Lindquist, S., & Stangel, M. (2011). Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatric Disease and Treatment, 341. https://doi.org/10.2147/ndt.s10464

Vancouver

Lindquist S, Stangel M. Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatric Disease and Treatment. 2011:341. doi:10.2147/ndt.s10464

BibTeX
@article{Lindquist2011,
  author = {Lindquist, Sabine and Stangel, Martin},
  title = {Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine},
  journal = {Neuropsychiatric Disease and Treatment},
  year = {2011},
  pages = {341},
  doi = {10.2147/ndt.s10464}
}
Kostenlos starten →